58 percent of post-mpox participants had at least one persistent sequela; most of these were appearance-related<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, Jan. 23, 2026 (HealthDay News) — At 11 to 18 months after acute mpox, post-mpox sequelae persist frequently, according to a study published online Jan. 20 in the Annals of Internal Medicine<\/em>.<\/p>\n Preetam A. Cholli, M.D., from the Centers for Disease Control and Prevention in Atlanta, and colleagues characterized post-mpox sequelae 11 to 18 months after acute mpox diagnosis in a cohort study conducted among adults attending HIV, preexposure prophylaxis, or sexually transmitted infection clinics, diagnosed with mpox during May 2022 to January 2023 (post-mpox; 154 patients) or at risk for but never diagnosed with mpox (no-mpox; 201 participants).<\/p>\n The researchers found that between the groups, the proportion of participants reporting increased psychobehavioral symptoms was generally similar. Eighty-nine of the post-mpox participants (58 percent) had at least one persistent sequela; 86 (56 percent) were related to appearance, and of these, 44 of 86 (51 percent) occurred at two or fewer sites. Twenty (13 percent) post-mpox participants had functional sequelae; 10 and seven had ongoing anorectal and urinary dysfunction, respectively.<\/p>\n “Our findings provide informative context for characterizing the types of, and risk for, persistent physical and psychosocial sequelae that may occur because of mpox,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n